|
"The few, the proud, the profitable" could be Genentech's motto. One of the world's most successful biotechs (in an industry full of money-losers), the firm has three billion-dollar blockbusters: Rituxan, which fights non-Hodgkin's lymphoma; Avastin, a treatment for colorectal, breast, and lung cancers; and Herceptin for breast cancer. Lung cancer drug Tarceva rounds out the company's oncology portfolio. Genentech's other marketed drugs include age-related macular degeneration treatment Lucentis, human growth hormone Nutropin, cystic fibrosis drug Pulmozyme, and asthma drug Xolair. Swiss drugmaker Roche, which previously owned a majority stake in the firm, took full ownership of Genentech in 2009.
|
| | | Contact Information | |
Address: |
1 DNA Way
South San Francisco, CA 94080
| | Phone: | 650-225-1000 | | Fax: | 650-225-6000 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 13418.00 M | | Employees (2008): | 11,174 |
|
|
Key People
| | • |
CEO:
Ian T. Clark
| | • |
VP Manufacturing Collaborations:
Philippa Norman
| | • |
EVP Head Global Development and Chief Medical Officer:
Hal V. Barron
|
|
|
